Review article: dose optimisation of infliximab for acute severe ulcerative colitis
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
SummaryBackgroundAlthough optimal medical management of acute severe ulcerative colitis (UC) is ill‐defined, infliximab has become a standard of care. Accumulating evidence suggests an increased rate of infliximab clearance in patients with acute severe UC and a reduced colectomy rate with an intensified infliximab induction regimen.AimTo assess the strength of the current evidence for the relationship between infliximab pharmacokinetics, dosing strategies and disease behaviour in patients with acute severe UC.MethodsWe systematically searched MEDLINE and conference proceedings from 2000 to 2016 for relevant articles describing the pharmacokinetics of infliximab in acute severe UC and/or infliximab dose intensification strategies in acute severe UC. Eligible articles described randomised controlled trials, and cohort, cross‐sectional, and case–controlled studies.ResultsOf 400 citations identified, 76 studies were eligible. Increased infliximab clearance occurs in patients with acute severe UC, and is driven by the total inflammatory burden and leakage of drug into the colonic lumen. Several cohort studies suggest that infliximab dose intensification is beneficial to at least 50% of acute severe UC patients and the results of case–controlled studies indicate that an intensified infliximab dosing regimen with 1–2 additional infusions in the first 3 weeks of treatment could reduce the early (3‐month) colectomy rate by up to 80%, although these data require prospective validation.ConclusionsUncontrolled studies suggest a benefit for infliximab dose optimisation in patients with acute severe UC. A randomised controlled trial in acute severe UC patients comparing a personalised infliximab dose‐optimisation strategy with conventional dosing is a research priority.
